Loading…

A three-year follow-up of congenital adrenal hyperplasia newborn screening

congenital adrenal hyperplasia (CAH) newborn screening can prevent neonatal mortality in children with the salt-wasting form of the disease and prevent incorrect gender assignments, which can occur in females. However, the occurrence of false-positive results in preterm or low-birth-weight newborns...

Full description

Saved in:
Bibliographic Details
Published in:Jornal de pediatria 2014-05, Vol.90 (3), p.300-307
Main Authors: Pezzuti, Isabela L., Barra, Cristina B., Mantovani, Rafael M., Januário, José N., Silva, Ivani N.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c505t-4e1035e6316c8d2476c8e81025c3ead9931c484ef62d6ea4bf2502f608824e673
cites cdi_FETCH-LOGICAL-c505t-4e1035e6316c8d2476c8e81025c3ead9931c484ef62d6ea4bf2502f608824e673
container_end_page 307
container_issue 3
container_start_page 300
container_title Jornal de pediatria
container_volume 90
creator Pezzuti, Isabela L.
Barra, Cristina B.
Mantovani, Rafael M.
Januário, José N.
Silva, Ivani N.
description congenital adrenal hyperplasia (CAH) newborn screening can prevent neonatal mortality in children with the salt-wasting form of the disease and prevent incorrect gender assignments, which can occur in females. However, the occurrence of false-positive results in preterm or low-birth-weight newborns creates some diagnostic difficulties, with consequent therapeutic implications. This study aimed to report the results of a pilot project for neonatal CAH screening conducted in the state of Minas Gerais, Brazil from 09/2007 to 05/2008 with a three-year follow-up. dried blood specimens were collected on filter paper cards three to seven days after birth of all newborns in the period. Samples were analyzed for 17-hydroxyprogesterone using an enzyme-linked immunosorbent assay (ELISA). a total of 159,415 children were screened. The apparent incidence of the classic variant of the disease was 1:9,963, based on initial diagnoses following newborn screening. During the follow-up period, eight of 16 children initially diagnosed with CAH were reclassified as unaffected, resulting in a revised incidence of 1:19,927. The false-positive rate was 0.31%, and the positive predictive value was 2.1%. Sensitivity and specificity were 100% and 99.7%, respectively. newborn screening is an important public health policy in developing countries such as Brazil, where CAH remains underdiagnosed. It has great potential to identify children with the disease who otherwise cannot be diagnosed earlier. Long-term follow-up and monitoring of all children with positive screening results are crucial to ensure a correct diagnosis and to calculate a reliable incidence ratio of the disease. a triagem neonatal para hiperplasia adrenal congênita (HAC) pode evitar a morte de recém-nascidos com a forma perdedora de sal e o registro civil incorreto das meninas. Entretanto, a ocorrência de resultados falso-positivos em recém-nascidos pré-termos ou com baixo peso ao nascer gera dificuldades diagnósticas, com consequentes implicações terapêuticas. O objetivo do estudo foi avaliar os resultados do projeto piloto de triagem neonatal para HAC realizado no estado de Minas Gerais, Brasil, de setembro de 2007 a maio de 2008 com acompanhamento de três anos. A dosagem da 17-hidroxiprogesterona foi realizada por ensaio imunoenzimático (ELISA), em amostras de sangue seco coletadas em papel-filtro, três a sete dias após o nascimento de todos os recém-nascidos no período. Foram triadas 159.415 crianças. Observou-se
doi_str_mv 10.1016/j.jped.2013.09.007
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_af86e469be484613a73cc7ae84398ff8</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><scielo_id>S0021_75572014000200300</scielo_id><els_id>S0021755714000242</els_id><doaj_id>oai_doaj_org_article_af86e469be484613a73cc7ae84398ff8</doaj_id><sourcerecordid>1523407293</sourcerecordid><originalsourceid>FETCH-LOGICAL-c505t-4e1035e6316c8d2476c8e81025c3ead9931c484ef62d6ea4bf2502f608824e673</originalsourceid><addsrcrecordid>eNp9UU1v1DAUtBCILgt_gAPKkUvC82cciUtVAS2qxAE4W17nZesoGwc7abX_HqdpOSJZGvl5ZvQ8Q8h7ChUFqj71VT9hWzGgvIKmAqhfkB1VtS5FrdlLsgNgtKylrC_Im5R6AKkaRV-TCyakAsmaHfl-Wcx3EbE8o41FF4YhPJTLVISucGE84uhnOxS2jThmvDtPGKfBJm-LER8OIY5Fclk--vH4lrzq7JDw3RPuye-vX35dXZe3P77dXF3elk6CnEuBFLhExalyumWizoCaApOOo22bhlMntMBOsVahFYeOSWCdAq2ZQFXzPbnZfNtgezNFf7LxbIL15nEQ4tHYOHs3oLGdVihUc8DsqCi3NXeutqgFb3TX6exVbV7JeRyC6cMS80eT-blmZ9bscrwC8g2A57MnHzfBFMOfBdNsTj45HAY7YliSoZJxATVreKayjepiSCli929XCmYt0PRmLdCsBRpoTC4wiz48-S-HU357ljw3lgmfNwLmiO89RrOuPjpsfUQ35wz8__z_AmWRqEk</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1523407293</pqid></control><display><type>article</type><title>A three-year follow-up of congenital adrenal hyperplasia newborn screening</title><source>ScienceDirect Journals</source><source>SciELO</source><creator>Pezzuti, Isabela L. ; Barra, Cristina B. ; Mantovani, Rafael M. ; Januário, José N. ; Silva, Ivani N.</creator><creatorcontrib>Pezzuti, Isabela L. ; Barra, Cristina B. ; Mantovani, Rafael M. ; Januário, José N. ; Silva, Ivani N.</creatorcontrib><description>congenital adrenal hyperplasia (CAH) newborn screening can prevent neonatal mortality in children with the salt-wasting form of the disease and prevent incorrect gender assignments, which can occur in females. However, the occurrence of false-positive results in preterm or low-birth-weight newborns creates some diagnostic difficulties, with consequent therapeutic implications. This study aimed to report the results of a pilot project for neonatal CAH screening conducted in the state of Minas Gerais, Brazil from 09/2007 to 05/2008 with a three-year follow-up. dried blood specimens were collected on filter paper cards three to seven days after birth of all newborns in the period. Samples were analyzed for 17-hydroxyprogesterone using an enzyme-linked immunosorbent assay (ELISA). a total of 159,415 children were screened. The apparent incidence of the classic variant of the disease was 1:9,963, based on initial diagnoses following newborn screening. During the follow-up period, eight of 16 children initially diagnosed with CAH were reclassified as unaffected, resulting in a revised incidence of 1:19,927. The false-positive rate was 0.31%, and the positive predictive value was 2.1%. Sensitivity and specificity were 100% and 99.7%, respectively. newborn screening is an important public health policy in developing countries such as Brazil, where CAH remains underdiagnosed. It has great potential to identify children with the disease who otherwise cannot be diagnosed earlier. Long-term follow-up and monitoring of all children with positive screening results are crucial to ensure a correct diagnosis and to calculate a reliable incidence ratio of the disease. a triagem neonatal para hiperplasia adrenal congênita (HAC) pode evitar a morte de recém-nascidos com a forma perdedora de sal e o registro civil incorreto das meninas. Entretanto, a ocorrência de resultados falso-positivos em recém-nascidos pré-termos ou com baixo peso ao nascer gera dificuldades diagnósticas, com consequentes implicações terapêuticas. O objetivo do estudo foi avaliar os resultados do projeto piloto de triagem neonatal para HAC realizado no estado de Minas Gerais, Brasil, de setembro de 2007 a maio de 2008 com acompanhamento de três anos. A dosagem da 17-hidroxiprogesterona foi realizada por ensaio imunoenzimático (ELISA), em amostras de sangue seco coletadas em papel-filtro, três a sete dias após o nascimento de todos os recém-nascidos no período. Foram triadas 159.415 crianças. Observou-se incidência de 1:9.963 para a forma clássica da doença, baseando-se nos diagnósticos iniciais. Durante o período de acompanhamento, 8 de 16 crianças inicialmente diagnosticadas com HAC foram reclassificadas como não afetadas, resultando em uma incidência corrigida de 1:19.927. A taxa de falsos positivos foi de 0,31%, e o valor preditivo positivo foi de 2,1%. A sensibilidade e a especificidade foram 100% e 99,7%, respectivamente. a triagem neonatal é uma importante política de saúde pública para países em desenvolvimento como o Brasil, onde a HAC continua subdiagnosticada. Ela possui grande potencial para identificar crianças que poderiam não ter a doença reconhecida precocemente. O acompanhamento em longo prazo e o monitoramento de todas as crianças com resultados positivos na triagem são cruciais para confirmação diagnóstica e para o correto cálculo da incidência da doença.</description><identifier>ISSN: 0021-7557</identifier><identifier>ISSN: 1678-4782</identifier><identifier>EISSN: 1678-4782</identifier><identifier>DOI: 10.1016/j.jped.2013.09.007</identifier><identifier>PMID: 24560529</identifier><language>eng</language><publisher>Brazil: Elsevier Editora Ltda</publisher><subject>17-alpha-Hydroxyprogesterone - blood ; 17-hidroxiprogesterona ; 17-hydroxyprogesterone ; Adrenal Hyperplasia, Congenital - complications ; Adrenal Hyperplasia, Congenital - diagnosis ; Adrenal Hyperplasia, Congenital - epidemiology ; Birth Weight ; Brazil - epidemiology ; Child, Preschool ; Congenital Adrenal Hyperplasia ; Diagnóstico Precoce ; Early Diagnosis ; Enzyme-Linked Immunosorbent Assay ; False Positive Reactions ; Female ; Follow-Up Studies ; Hiperplasia Adrenal Congênita ; Humans ; Incidence ; Infant ; Infant, Newborn ; Male ; Neonatal Screening ; Neonatal Screening - methods ; PEDIATRICS ; Pilot Projects ; Predictive Value of Tests ; Sensitivity and Specificity ; Triagem Neonatal ; Virilism - etiology</subject><ispartof>Jornal de pediatria, 2014-05, Vol.90 (3), p.300-307</ispartof><rights>2014 Sociedade Brasileira de Pediatria</rights><rights>Copyright © 2014 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda. All rights reserved.</rights><rights>This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c505t-4e1035e6316c8d2476c8e81025c3ead9931c484ef62d6ea4bf2502f608824e673</citedby><cites>FETCH-LOGICAL-c505t-4e1035e6316c8d2476c8e81025c3ead9931c484ef62d6ea4bf2502f608824e673</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0021755714000242$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,3536,24129,27901,27902,45756</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24560529$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pezzuti, Isabela L.</creatorcontrib><creatorcontrib>Barra, Cristina B.</creatorcontrib><creatorcontrib>Mantovani, Rafael M.</creatorcontrib><creatorcontrib>Januário, José N.</creatorcontrib><creatorcontrib>Silva, Ivani N.</creatorcontrib><title>A three-year follow-up of congenital adrenal hyperplasia newborn screening</title><title>Jornal de pediatria</title><addtitle>J Pediatr (Rio J)</addtitle><description>congenital adrenal hyperplasia (CAH) newborn screening can prevent neonatal mortality in children with the salt-wasting form of the disease and prevent incorrect gender assignments, which can occur in females. However, the occurrence of false-positive results in preterm or low-birth-weight newborns creates some diagnostic difficulties, with consequent therapeutic implications. This study aimed to report the results of a pilot project for neonatal CAH screening conducted in the state of Minas Gerais, Brazil from 09/2007 to 05/2008 with a three-year follow-up. dried blood specimens were collected on filter paper cards three to seven days after birth of all newborns in the period. Samples were analyzed for 17-hydroxyprogesterone using an enzyme-linked immunosorbent assay (ELISA). a total of 159,415 children were screened. The apparent incidence of the classic variant of the disease was 1:9,963, based on initial diagnoses following newborn screening. During the follow-up period, eight of 16 children initially diagnosed with CAH were reclassified as unaffected, resulting in a revised incidence of 1:19,927. The false-positive rate was 0.31%, and the positive predictive value was 2.1%. Sensitivity and specificity were 100% and 99.7%, respectively. newborn screening is an important public health policy in developing countries such as Brazil, where CAH remains underdiagnosed. It has great potential to identify children with the disease who otherwise cannot be diagnosed earlier. Long-term follow-up and monitoring of all children with positive screening results are crucial to ensure a correct diagnosis and to calculate a reliable incidence ratio of the disease. a triagem neonatal para hiperplasia adrenal congênita (HAC) pode evitar a morte de recém-nascidos com a forma perdedora de sal e o registro civil incorreto das meninas. Entretanto, a ocorrência de resultados falso-positivos em recém-nascidos pré-termos ou com baixo peso ao nascer gera dificuldades diagnósticas, com consequentes implicações terapêuticas. O objetivo do estudo foi avaliar os resultados do projeto piloto de triagem neonatal para HAC realizado no estado de Minas Gerais, Brasil, de setembro de 2007 a maio de 2008 com acompanhamento de três anos. A dosagem da 17-hidroxiprogesterona foi realizada por ensaio imunoenzimático (ELISA), em amostras de sangue seco coletadas em papel-filtro, três a sete dias após o nascimento de todos os recém-nascidos no período. Foram triadas 159.415 crianças. Observou-se incidência de 1:9.963 para a forma clássica da doença, baseando-se nos diagnósticos iniciais. Durante o período de acompanhamento, 8 de 16 crianças inicialmente diagnosticadas com HAC foram reclassificadas como não afetadas, resultando em uma incidência corrigida de 1:19.927. A taxa de falsos positivos foi de 0,31%, e o valor preditivo positivo foi de 2,1%. A sensibilidade e a especificidade foram 100% e 99,7%, respectivamente. a triagem neonatal é uma importante política de saúde pública para países em desenvolvimento como o Brasil, onde a HAC continua subdiagnosticada. Ela possui grande potencial para identificar crianças que poderiam não ter a doença reconhecida precocemente. O acompanhamento em longo prazo e o monitoramento de todas as crianças com resultados positivos na triagem são cruciais para confirmação diagnóstica e para o correto cálculo da incidência da doença.</description><subject>17-alpha-Hydroxyprogesterone - blood</subject><subject>17-hidroxiprogesterona</subject><subject>17-hydroxyprogesterone</subject><subject>Adrenal Hyperplasia, Congenital - complications</subject><subject>Adrenal Hyperplasia, Congenital - diagnosis</subject><subject>Adrenal Hyperplasia, Congenital - epidemiology</subject><subject>Birth Weight</subject><subject>Brazil - epidemiology</subject><subject>Child, Preschool</subject><subject>Congenital Adrenal Hyperplasia</subject><subject>Diagnóstico Precoce</subject><subject>Early Diagnosis</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>False Positive Reactions</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Hiperplasia Adrenal Congênita</subject><subject>Humans</subject><subject>Incidence</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Male</subject><subject>Neonatal Screening</subject><subject>Neonatal Screening - methods</subject><subject>PEDIATRICS</subject><subject>Pilot Projects</subject><subject>Predictive Value of Tests</subject><subject>Sensitivity and Specificity</subject><subject>Triagem Neonatal</subject><subject>Virilism - etiology</subject><issn>0021-7557</issn><issn>1678-4782</issn><issn>1678-4782</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNp9UU1v1DAUtBCILgt_gAPKkUvC82cciUtVAS2qxAE4W17nZesoGwc7abX_HqdpOSJZGvl5ZvQ8Q8h7ChUFqj71VT9hWzGgvIKmAqhfkB1VtS5FrdlLsgNgtKylrC_Im5R6AKkaRV-TCyakAsmaHfl-Wcx3EbE8o41FF4YhPJTLVISucGE84uhnOxS2jThmvDtPGKfBJm-LER8OIY5Fclk--vH4lrzq7JDw3RPuye-vX35dXZe3P77dXF3elk6CnEuBFLhExalyumWizoCaApOOo22bhlMntMBOsVahFYeOSWCdAq2ZQFXzPbnZfNtgezNFf7LxbIL15nEQ4tHYOHs3oLGdVihUc8DsqCi3NXeutqgFb3TX6exVbV7JeRyC6cMS80eT-blmZ9bscrwC8g2A57MnHzfBFMOfBdNsTj45HAY7YliSoZJxATVreKayjepiSCli929XCmYt0PRmLdCsBRpoTC4wiz48-S-HU357ljw3lgmfNwLmiO89RrOuPjpsfUQ35wz8__z_AmWRqEk</recordid><startdate>20140501</startdate><enddate>20140501</enddate><creator>Pezzuti, Isabela L.</creator><creator>Barra, Cristina B.</creator><creator>Mantovani, Rafael M.</creator><creator>Januário, José N.</creator><creator>Silva, Ivani N.</creator><general>Elsevier Editora Ltda</general><general>Sociedade Brasileira de Pediatria</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>GPN</scope><scope>DOA</scope></search><sort><creationdate>20140501</creationdate><title>A three-year follow-up of congenital adrenal hyperplasia newborn screening</title><author>Pezzuti, Isabela L. ; Barra, Cristina B. ; Mantovani, Rafael M. ; Januário, José N. ; Silva, Ivani N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c505t-4e1035e6316c8d2476c8e81025c3ead9931c484ef62d6ea4bf2502f608824e673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>17-alpha-Hydroxyprogesterone - blood</topic><topic>17-hidroxiprogesterona</topic><topic>17-hydroxyprogesterone</topic><topic>Adrenal Hyperplasia, Congenital - complications</topic><topic>Adrenal Hyperplasia, Congenital - diagnosis</topic><topic>Adrenal Hyperplasia, Congenital - epidemiology</topic><topic>Birth Weight</topic><topic>Brazil - epidemiology</topic><topic>Child, Preschool</topic><topic>Congenital Adrenal Hyperplasia</topic><topic>Diagnóstico Precoce</topic><topic>Early Diagnosis</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>False Positive Reactions</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Hiperplasia Adrenal Congênita</topic><topic>Humans</topic><topic>Incidence</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Male</topic><topic>Neonatal Screening</topic><topic>Neonatal Screening - methods</topic><topic>PEDIATRICS</topic><topic>Pilot Projects</topic><topic>Predictive Value of Tests</topic><topic>Sensitivity and Specificity</topic><topic>Triagem Neonatal</topic><topic>Virilism - etiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pezzuti, Isabela L.</creatorcontrib><creatorcontrib>Barra, Cristina B.</creatorcontrib><creatorcontrib>Mantovani, Rafael M.</creatorcontrib><creatorcontrib>Januário, José N.</creatorcontrib><creatorcontrib>Silva, Ivani N.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>SciELO</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Jornal de pediatria</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pezzuti, Isabela L.</au><au>Barra, Cristina B.</au><au>Mantovani, Rafael M.</au><au>Januário, José N.</au><au>Silva, Ivani N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A three-year follow-up of congenital adrenal hyperplasia newborn screening</atitle><jtitle>Jornal de pediatria</jtitle><addtitle>J Pediatr (Rio J)</addtitle><date>2014-05-01</date><risdate>2014</risdate><volume>90</volume><issue>3</issue><spage>300</spage><epage>307</epage><pages>300-307</pages><issn>0021-7557</issn><issn>1678-4782</issn><eissn>1678-4782</eissn><abstract>congenital adrenal hyperplasia (CAH) newborn screening can prevent neonatal mortality in children with the salt-wasting form of the disease and prevent incorrect gender assignments, which can occur in females. However, the occurrence of false-positive results in preterm or low-birth-weight newborns creates some diagnostic difficulties, with consequent therapeutic implications. This study aimed to report the results of a pilot project for neonatal CAH screening conducted in the state of Minas Gerais, Brazil from 09/2007 to 05/2008 with a three-year follow-up. dried blood specimens were collected on filter paper cards three to seven days after birth of all newborns in the period. Samples were analyzed for 17-hydroxyprogesterone using an enzyme-linked immunosorbent assay (ELISA). a total of 159,415 children were screened. The apparent incidence of the classic variant of the disease was 1:9,963, based on initial diagnoses following newborn screening. During the follow-up period, eight of 16 children initially diagnosed with CAH were reclassified as unaffected, resulting in a revised incidence of 1:19,927. The false-positive rate was 0.31%, and the positive predictive value was 2.1%. Sensitivity and specificity were 100% and 99.7%, respectively. newborn screening is an important public health policy in developing countries such as Brazil, where CAH remains underdiagnosed. It has great potential to identify children with the disease who otherwise cannot be diagnosed earlier. Long-term follow-up and monitoring of all children with positive screening results are crucial to ensure a correct diagnosis and to calculate a reliable incidence ratio of the disease. a triagem neonatal para hiperplasia adrenal congênita (HAC) pode evitar a morte de recém-nascidos com a forma perdedora de sal e o registro civil incorreto das meninas. Entretanto, a ocorrência de resultados falso-positivos em recém-nascidos pré-termos ou com baixo peso ao nascer gera dificuldades diagnósticas, com consequentes implicações terapêuticas. O objetivo do estudo foi avaliar os resultados do projeto piloto de triagem neonatal para HAC realizado no estado de Minas Gerais, Brasil, de setembro de 2007 a maio de 2008 com acompanhamento de três anos. A dosagem da 17-hidroxiprogesterona foi realizada por ensaio imunoenzimático (ELISA), em amostras de sangue seco coletadas em papel-filtro, três a sete dias após o nascimento de todos os recém-nascidos no período. Foram triadas 159.415 crianças. Observou-se incidência de 1:9.963 para a forma clássica da doença, baseando-se nos diagnósticos iniciais. Durante o período de acompanhamento, 8 de 16 crianças inicialmente diagnosticadas com HAC foram reclassificadas como não afetadas, resultando em uma incidência corrigida de 1:19.927. A taxa de falsos positivos foi de 0,31%, e o valor preditivo positivo foi de 2,1%. A sensibilidade e a especificidade foram 100% e 99,7%, respectivamente. a triagem neonatal é uma importante política de saúde pública para países em desenvolvimento como o Brasil, onde a HAC continua subdiagnosticada. Ela possui grande potencial para identificar crianças que poderiam não ter a doença reconhecida precocemente. O acompanhamento em longo prazo e o monitoramento de todas as crianças com resultados positivos na triagem são cruciais para confirmação diagnóstica e para o correto cálculo da incidência da doença.</abstract><cop>Brazil</cop><pub>Elsevier Editora Ltda</pub><pmid>24560529</pmid><doi>10.1016/j.jped.2013.09.007</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0021-7557
ispartof Jornal de pediatria, 2014-05, Vol.90 (3), p.300-307
issn 0021-7557
1678-4782
1678-4782
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_af86e469be484613a73cc7ae84398ff8
source ScienceDirect Journals; SciELO
subjects 17-alpha-Hydroxyprogesterone - blood
17-hidroxiprogesterona
17-hydroxyprogesterone
Adrenal Hyperplasia, Congenital - complications
Adrenal Hyperplasia, Congenital - diagnosis
Adrenal Hyperplasia, Congenital - epidemiology
Birth Weight
Brazil - epidemiology
Child, Preschool
Congenital Adrenal Hyperplasia
Diagnóstico Precoce
Early Diagnosis
Enzyme-Linked Immunosorbent Assay
False Positive Reactions
Female
Follow-Up Studies
Hiperplasia Adrenal Congênita
Humans
Incidence
Infant
Infant, Newborn
Male
Neonatal Screening
Neonatal Screening - methods
PEDIATRICS
Pilot Projects
Predictive Value of Tests
Sensitivity and Specificity
Triagem Neonatal
Virilism - etiology
title A three-year follow-up of congenital adrenal hyperplasia newborn screening
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T10%3A07%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20three-year%20follow-up%20of%20congenital%20adrenal%20hyperplasia%20newborn%20screening&rft.jtitle=Jornal%20de%20pediatria&rft.au=Pezzuti,%20Isabela%20L.&rft.date=2014-05-01&rft.volume=90&rft.issue=3&rft.spage=300&rft.epage=307&rft.pages=300-307&rft.issn=0021-7557&rft.eissn=1678-4782&rft_id=info:doi/10.1016/j.jped.2013.09.007&rft_dat=%3Cproquest_doaj_%3E1523407293%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c505t-4e1035e6316c8d2476c8e81025c3ead9931c484ef62d6ea4bf2502f608824e673%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1523407293&rft_id=info:pmid/24560529&rft_scielo_id=S0021_75572014000200300&rfr_iscdi=true